GenoMed CEO Invited to Speak at World DNA Day in China
Apr 29, 2005, 20:08, Reviewed by: Dr.
|
|
"It's an extraordinary honor to be invited to such a prestigious gathering of Nobel prize-winners and other scientific luminaries. Genomics is fulfilling the hope that thousands of physician-scientists have entertained for several thousand years: to find the source of human diseases so we can stop them. It's like finding the headwaters of a river in order to dam it."
|
By GenoMed, Inc.,
GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, was invited to speak yesterday at World DNA and Genome Day in Dalian, China (www.dnaday.com) on "Genomics and Cardiovascular Disease."
Said Dr. Moskowitz, "It's an extraordinary honor to be invited to such a prestigious gathering of Nobel prize-winners and other scientific luminaries. Genomics is fulfilling the hope that thousands of physician-scientists have entertained for several thousand years: to find the source of human diseases so we can stop them. It's like finding the headwaters of a river in order to dam it."
Dr. Moskowitz continued, "Overactivity of angiotensin I-converting enzyme, known as 'ACE,' seems to be the cause of most diseases of aging, including cardiovascular disease and cancer, the two main causes of death in the U.S. Inhibitors of ACE have been used for over 25 years, although not in the doses pioneered by GenoMed. Actual patient outcomes over the next decade or two will prove whether we've found the Fountain of Youth or not. This hypothesis comes at a good time for Baby Boomers like me." 
- GenoMed, Inc.
www.genomed.com
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. DM (Disease Management) is the only industry in healthcare which profits by lowering healthcare costs. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether ACE is the major aging gene; (b) whether we will have sufficient financing to conduct our research and development; and (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
